Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non Operating Income (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Non Operating Income for 4 consecutive years, with -$61.1 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 306.25% to -$61.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$76.0 million through Dec 2025, down 72.61% year-over-year, with the annual reading at -$61.3 million for FY2025, 7.74% down from the prior year.
  • Non Operating Income for Q4 2025 was -$61.1 million at Phathom Pharmaceuticals, down from -$14.7 million in the prior quarter.
  • The five-year high for Non Operating Income was $20000.0 in Q1 2023, with the low at -$61.1 million in Q4 2025.
  • Average Non Operating Income over 4 years is -$9.5 million, with a median of -$7.0 million recorded in 2022.
  • The sharpest move saw Non Operating Income surged 385.71% in 2023, then plummeted 471633.33% in 2024.
  • Over 4 years, Non Operating Income stood at -$8.4 million in 2022, then dropped by 15.35% to -$9.7 million in 2023, then crashed by 55.07% to -$15.0 million in 2024, then crashed by 306.25% to -$61.1 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$61.1 million, -$14.7 million, and -$155000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.